START-POAF -SHORT TERM ANTI-ARRHYTHMIC THERAPY FOR POST-OPERATIVE AF IN CARDIAC SURGERY PATIENTS (START-POAF) PILOT TRIAL

Registry ID

2023.START-POAF

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

HAMILTON HEALTH SCIENCES CORPORATION

Start date

2024-05-09

Last update

2023-07-26

Conditions

• ATRIAL FIBRILLATION

Related clinical trials

• A PHASE 2, RANDOMIZED, MULTICENTER, OPEN-LABEL, BLINDED-ENDPOINT STUDY TO EVALUATE THE SAFETY OF REGN7508 AND REGN9933, MONOCLONAL ANTIBODIES AGAINST FXI, VERSUS APIXABAN IN PARTICIPANTS WITH ATRIAL FIBRILLATION (ROXI-ATLAS)
• A RANDOMIZED, PLACEBO-CONTROLLED, PARTICIPANT- AND INVESTIGATOR-BLINDED STUDY TO EVALUATE THE EFFICACY IN REDUCING ATRIAL FIBRILLATION BURDEN (AFB) AS WELL AS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ORAL PKN605 IN PARTICIPANTS WITH ATRIAL FIBRILLATION
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, ACTIVE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MILVEXIAN, AN ORAL FACTOR XIA INHIBITOR, VERSUS APIXABAN IN PARTICIPANTS WITH ATRIAL FIBRILLATION
• USE OF MAGNESIUM PROPHYLAXIS FOR THE PREVENTION OF ATRIAL FIBRILLATION IN CRITICALLY ILL PATIENTS : ATOMIC PILOT STUDY
• A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABELACIMAB IN HIGH-RISK PATIENTS WITH ATRIAL FIBRILLATION WHO HAVE BEEN DEEMED UNSUITABLE FOR ORAL ANTICOAGULATION (LILAC), VERSION 1.0 DATED 18 OCTOBER 2022
• A PHASE 2, TWO-STAGE, SERIAL COHORT DOSE ESCALATION AND EXPANSION STUDY OF A SINGLE INTRAVENOUS INFUSION OF HBI 3000 FOR THE CONVERSION OF ATRIAL FIBRILLATION (AF) OF RECENT ONSET

View on source registry